NCT05224804

Brief Summary

The present study has assessed the knowledge, attitude and practice of ADRs reporting among pharmacists, and the perceived factors that may influence reporting.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2020

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 10, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 10, 2021

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 29, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 4, 2022

Completed
Last Updated

February 4, 2022

Status Verified

January 1, 2022

Enrollment Period

1.4 years

First QC Date

January 29, 2022

Last Update Submit

February 3, 2022

Conditions

Adverse Drug Reaction

Outcome Measures

Primary Outcomes (1)

  • Pharmacists' Knowledge and Attitudes about ADRs Reporting and Pharmacovigilance Practice in Egyptian Hospitals

    The majority of pharmacists was knowledgeable about pharmacovigilance and had a favourable attitude toward ADR reporting. There are several variables that discourage pharmacists from reporting suspected ADRs, including the belief that there is no advantage to reporting, the presence of administrative barriers, the lack of availability of the ADR reporting form, and the lack of encouragement from hospital administration.

    1 year and 4 month to collect data.

Interventions

knwoledgeBEHAVIORAL

Knowledge and Attitudes about ADRs Reporting

Eligibility Criteria

Age20 Years - 50 Years
Sexall
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

A total of 300 pharmacists were approached and questionnaire forms were distributed to pharmacists in different practice settings. Questionnaire was handed to them after explaining them the aim of the study. The pharmacists were asked to complete the questionnaire and hand it back after completion, Descriptive statistics including frequency and percentage was used to present the data.

You may qualify if:

  • \- Pharmacist graduates

You may not qualify if:

  • undergrauate pharmacist

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Marwa Kamal Ahmed Tolba

Al Fayyum, 63111, Egypt

Location

Related Publications (1)

  • Beninger P. Pharmacovigilance: An Overview. Clin Ther. 2018 Dec;40(12):1991-2004. doi: 10.1016/j.clinthera.2018.07.012. Epub 2018 Aug 17.

    PMID: 30126707BACKGROUND

MeSH Terms

Conditions

Drug-Related Side Effects and Adverse Reactions

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of clinical pharmacy, phD

Study Record Dates

First Submitted

January 29, 2022

First Posted

February 4, 2022

Study Start

May 1, 2020

Primary Completion

September 10, 2021

Study Completion

September 10, 2021

Last Updated

February 4, 2022

Record last verified: 2022-01

Locations

EG(1)